StreetInsider.com News Articles

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

Mon, 27 Jul 2026 08:00:00 -0400

New division will address the limitations of traditional peptide compounding through 3D printing and AI

PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform

Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today the launch of Personaliz3D Peptides™, a new division focused on developing and commercializing personalized peptide products and protocols using 3D printing and artificial intelligence technologies.

Patients and healthcare

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

Mon, 27 Jul 2026 08:00:00 -0400

New division will address the limitations of traditional peptide compounding through 3D printing and AI

PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform

Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

Patients and healthcare

PharmaTher partners with KetaMist inventor to seek FDA approval

Tue, 21 Jul 2026 08:02:13 -0400

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced a collaboration with Curtis W. Cassidy, M.D., the developer of KetaMist, a needle-free ketamine treatment platform, to pursue U.S. Food and Drug Administration approval for treatment-resistant depression and other neuropsychiatric conditions.

According to the company's press release, KetaMist has been used in more than 9,000 patient treatments to date. The platform is designed as a patient-controlled, needle-free delivery system intended to allow physicians to tailor ketamine dosing to individual patient response.

PharmaTher said it plans to apply regulatory and chemistry, manufacturing and controls experience from its prior FDA ketamine work to the KetaMist program.

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience

Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W. Cassidy, M.D., the inventor and developer of KetaMist® (ketamist.com), a needle-free ketamine treatment platform, to

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

Tue, 21 Jul 2026 08:00:00 -0400

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience

Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation

KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Wed, 15 Jul 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics.

PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printing platform and AI-driven formulation tools. The Company's main focus is personalized medicines, aiming to develop treatments tailored to individual patient needs.

"Medicine is shifting toward treatments tailored to each patient," said Fabio Chianelli, Chairman and Chief Executive Officer of

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

Wed, 15 Jul 2026 08:00:00 -0400

"Medicine is shifting toward treatments tailored to each patient," said Fabio Chianelli, Chairman and Chief Executive Officer of

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Wed, 27 May 2026 08:00:00 -0400

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats

Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings

Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company's robotic 3D printing

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Wed, 27 May 2026 08:00:00 -0400

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Wed, 13 May 2026 10:11:00 -0400

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo's patented, orally bioavailable PD-001 cepharanthine formulation for Hantavirus

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate for Hantavirus ("HTNV").

Independent published research has identified cepharanthine

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Wed, 13 May 2026 10:11:00 -0400

Independent published research has identified cepharanthine

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Wed, 13 May 2026 08:50:00 -0400

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantavirus

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 51% owned by PharmaDrug and 49% owned by PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher"), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Wed, 13 May 2026 08:50:00 -0400

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

Tue, 21 Apr 2026 08:00:00 -0400

Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transaction

Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental Illness," signed on April 18, 2026, may help create a more supportive political and regulatory backdrop for innovative ketamine-based programs, particularly where severe unmet need, depression, suicidality, and other difficult-to-treat mental health conditions are involved.

"We

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

Tue, 21 Apr 2026 08:00:00 -0400

"We

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

Mon, 20 Apr 2026 08:00:00 -0400

U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an attractive solution for compounding pharmacies, hospitals, research institutions, and commercial partners

Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies, believes it is well-positioned to benefit from two major U.S. regulatory developments: growing federal support for psychedelic medicine and advancing efforts to restore broader compounding access for select therapeutic peptides.

Two major U.S. federal shifts have created a compelling

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

Mon, 20 Apr 2026 08:00:00 -0400

Two major U.S. federal shifts have created a compelling

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

Thu, 16 Apr 2026 08:00:00 -0400

Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-generation peptide delivery

Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed support for recent U.S. initiatives led by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and the U.S. Food and Drug Administration (FDA) to revisit the regulatory treatment of select therapeutic peptides.

"We applaud Secretary Kennedy and the FDA for advancing a

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

Thu, 16 Apr 2026 08:00:00 -0400

"We applaud Secretary Kennedy and the FDA for advancing a

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

Mon, 13 Apr 2026 08:00:00 -0400

Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development and commercialization strategy

Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States Patent and Trademark Office, titled "Stabilized Peptide Compositions for Microneedle and Transdermal Delivery." The patent filing covers formulation technologies designed to help protect peptides from degradation during manufacturing, drying, storage and use, supporting PharmaPatch™ as PharmaTher's product strategy

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

Mon, 13 Apr 2026 08:00:00 -0400

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Thu, 26 Mar 2026 08:00:00 -0400

Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide patches, branded wellness patches, manufacturing systems and commercial partnerships.

Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional patent application to USPTO for PatchPrint™, its Automated Tabletop Microneedle Patch 3D Printer. The application is titled "Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging, and Multi-Product Cargo-Adaptive Processing" (Application No. 64/015,408). PatchPrint™ is intended to support and scale

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

Thu, 26 Mar 2026 08:00:00 -0400

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent entry into GLP-1 delivery using PharmaPatch™.

"Building on our ketamine and psychedelics patch programs and our expansion into GLP-1 delivery, we are now broadening PharmaPatch™ to evaluate select peptide candidates where a needle-free, at-home patch could

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 -0400